Tobacco & Nicotine Harm Reduction

Advancing Tobacco & Nicotine Harm Reduction Research

CenExel partners with sponsors to evaluate innovative tobacco harm reduction and nicotine delivery solutions through scientifically rigorous clinical research. Our experienced research teams support studies focused on behavioral science, product evaluation, abuse liability, and reduced-risk nicotine alternatives across diverse adult populations.

Studies Conducted
0 +
Trial Participants
0 +
Active Centers
0
Overview

Specialized Research for Tobacco & Nicotine Innovation

CenExel provides end-to-end clinical research support for tobacco harm reduction and nicotine-related studies. Our multidisciplinary teams deliver operational excellence, participant recruitment expertise, and high-quality data collection to help sponsors evaluate emerging products and behavioral outcomes with confidence.

Conditions Covered

Tobacco & Nicotine Research Focus Areas

Our research programs support a wide range of tobacco harm reduction and nicotine-related clinical studies.

  • Tobacco Harm Reduction
  • Nicotine Replacement Therapies
  • Electronic Nicotine Delivery Systems (ENDS)
  • Smoking Cessation Studies
  • Behavioral Dependence Research
  • Reduced-Risk Product Evaluation
  • Abuse Liability Assessment
  • Dual Use Behavior Studies
Our Approach

Why Sponsors Choose CenExel for Tobacco & Nicotine Research

CenExel combines experienced investigators, advanced participant recruitment strategies, and operational excellence to support successful tobacco and nicotine harm reduction clinical trials.

01

Experienced Research Teams

Our investigators support complex tobacco and nicotine studies with high-quality clinical oversight and regulatory expertise.

02

Diverse Participant Access

Access to active smokers, former smokers, dual users, and nicotine-dependent populations across multiple demographics.

03

Behavioral & Product Expertise

Support for behavioral interventions, digital cessation programs, nicotine replacement therapies, and reduced-risk product studies.

04

Rapid Enrollment

Our centralized recruitment and site network accelerate enrollment timelines for tobacco and nicotine trials.

Phase Coverage

Supported Tobacco & Nicotine Trial Phases

CenExel supports early and late-phase tobacco and nicotine harm reduction studies — from first-in-human product evaluations through large-scale post-market research.

Active across all phases
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Let’s Advance Your Next Study

Looking for an experienced clinical research partner with the expertise, capabilities, and reach to move your study forward? Connect with CenExel to discuss your needs and explore how our network can support your clinical development goals.

Explore Our Network

Discover CenExel’s Centers of Excellence and find the locations, therapeutic expertise, and capabilities that align with your clinical development needs.

Our Blog